Structural Uncertainty of Markov Models for Advanced Breast Cancer: A Simulation Study of Lapatinib
Conclusions. Our study shows that modeling ABC with different Markov model structures yielded a wide range of cost-effectiveness results, suggesting the need to investigate structural uncertainty in health economic evaluation. When applied in the context of HER2-positive ABC treatment, the combination therapy with lapatinib is not cost-effective, regardless of which model was used and whether uncertainties were accounted for.
Source: Medical Decision Making - Category: Health Management Authors: Le, Q. A. Tags: Original Articles Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Health | Health Management | HER2 | Study | Xeloda